Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262939 | 0.97 | PTPN1 (0.48) | PTPN1ABL1FLT3JAK2JAK1 | |
| SCHEMBL2936203 | 0.86 | PTPN1 (0.48) | PTPN1JAK2JAK1PRMT5WDR77 | |
| SCHEMBL3213594 | 0.85 | PTPN1 (0.53) | PTPN1FLT3PRMT5WDR77CTSK | |
| SCHEMBL3220712 | 0.84 | PTPN1 (0.48) | PTPN1ABL1PRMT5WDR77PTPN2 | |
| SCHEMBL2937480 | 0.84 | PTPN1 (0.50) | PTPN1PRMT5WDR77PTPN2 | |
| SCHEMBL31328076 | 0.84 | PTPN1 (0.50) | PTPN1PRMT5WDR77PTPN2 | |
| SCHEMBL3226584 | 0.82 | PTPN1 (0.52) | PTPN1FLT3JAK2PRMT5WDR77 | |
| SCHEMBL2936717 | 0.82 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL2930306 | 0.80 | PTPN1 (0.58) | PTPN1PRMT5WDR77USP30PTPN2 | |
| SCHEMBL3201397 | 0.77 | PTPN1 (0.53) | PTPN1FLT3PRMT5WDR77CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | PTPN1 10/4885ABL1 698/4885FLT3 2477/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885ABL1 88/4885FLT3 1117/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885ABL1 112/4885FLT3 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.